FDA Approval of KEYTRUDA for Treatment of Gastric Cancer [transcript][audio]
Key Takeaways
- Key Insight: Presenter: Neal Howard Guest Bio: Charles S.
- Clinical Perspective: Fuchs, MD, MPH, became Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital on January 1, 2017.
- Why It Matters: This discussion provides healthcare professionals with actionable insights relevant to clinical practice and patient care.
- Key Point: Listen to the full episode for detailed discussion and professional insights on this important healthcare topic.
- Key Point: Listen to the full episode for detailed discussion and professional insights on this important healthcare topic.
Guest: Dr. Charles S. Fuchs, M.D.
Presenter: Neal Howard
Guest Bio: Charles S. Fuchs, MD, MPH, became Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital on January 1, 2017. An internationally recognized expert in gastrointestinal cancers and cancer epidemiology, Dr. Fuchs was previously professor of medicine at Harvard Medical School and chief of the gastrointestinal oncology division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. Dr. Fuchs received his medical degree from Harvard Medical School in 1986. He completed his medical residency at Brigham and Women’s Hospital, where he also served as chief medical resident and completed his medical oncology fellowship at Dana-Farber Cancer Institute. In 1994, he received his M.P.H. from Harvard School of Public Health.
Segment Overview: Dr. Charles S. Fuchs discusses the recent FDA approval of KEYTRUDA (pembrolizumab) for patients with advanced gastric cancer that have received 2 or more lines of chemotherapy, and what this means for patients, doctors, and caregivers.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
